Neutrophil degranulation and immunosuppression in patients with GBM: Restoration of cellular immune function by targeting arginase I

Clinical Cancer Research

Volumn 17, Issue 22, 2011, Pages 6992-7002

  Sippel, Trisha R ^a,b   White, Jason ^a   Nag, Kamalika ^c   Tsvankin, Vadim ^a   Klaassen, Marci ^a   Kleinschmidt DeMasters, B K ^a   Waziri, Allen ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; ARGININE; CD11B ANTIGEN; CD3 ANTIGEN; CD3 ZETA ANTIGEN; MITOGENIC AGENT; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL EXPANSION; CELL LINEAGE; CELL POPULATION; CELL SELECTION; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; DEGRANULATION; ENZYME INHIBITION; EX VIVO STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOASSAY; IN VITRO STUDY; INTRACRANIAL TUMOR; LYMPHOCYTE FUNCTION; NEUTROPHIL DEGRANULATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY;

ARGINASE; ARGININE; BRAIN NEOPLASMS; CELL DEGRANULATION; CELLS, CULTURED; GLIOBLASTOMA; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; MOLECULAR TARGETED THERAPY; NEUTROPHILS; T-LYMPHOCYTES;

EID: 81255129169     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1107     Document Type: Article

References (30)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
2. Rolle CE, Sengupta S, Lesniak MS. Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurg Clin N Am 2010;21:201-14.
3. Waziri A. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am 2010;21:31-42.
4. + T cell activation and expansion within human glioblastoma. J Immunol 2008;180:7673-80.
5. Brooks WH, Latta RB, Mahaley MS, Roszman TL, Dudka L, Skaggs C. Immunobiology of primary intracranial tumors. Part 5: correlation of a lymphocyte index and clinical status. J Neurosurg 1981;54:331-7. (Pubitemid 11135940)
6. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008;222:162-79. (Pubitemid 351430364)
7. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
8. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010;22:238-44.
9. Serfani P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65. (Pubitemid 43139709)
10. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4Rα+myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009;182:6562-8.
11. +HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010;12:631-44.
12. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM, et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 2005;105: 2549-56. (Pubitemid 40387058)
13. Fossati G, Ricevuti G, Edwards SW, Walker C, Dalton A, Rossi ML. Neutrophil infiltration into human gliomas. Acta Neuropathol 1999; 98:349-54. (Pubitemid 29440680)
14. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003;171: 1232-9. (Pubitemid 36900052)
15. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8. (Pubitemid 40524582)
16. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. ArginaseI-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69:1553-60.
17. Rotondo R, Barisione G, Mastracci L, Grossi F, Orengo AM, Costa R, et al. IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J Cancer 2009; 125:887-93.
18. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanisms of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61: 4756-60. (Pubitemid 32691887)
19. Youn JI, Srinivas N, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181: 5791-802.
20. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008;111: 4233-44.
21. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010; 12:351-65.
22. Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, et al. Suppression of T-cell functions by human granulocyte arginase. Blood 2006;108:1627-34. (Pubitemid 44316131)
23. + T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136:35-45.
24. Rodriquez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008;222:180-91. (Pubitemid 351430370)
25. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006;6:173-82. (Pubitemid 43290987)
26. Rong Y, Durden D, Van Meir EG, Brat DJ. 'Psuedopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia and angiogenesis.J Neuropathol Exp Neurol 2006;65:529-39. (Pubitemid 44288937)
27. Waugh DJ, Wilson C. The Interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-41.
28. Neilly PJD, Kirk SJ, Gardiner KR, Rowlands BJ. The L-arginine/nitric oxide pathway-biological properties and therapeutic applications. Ulster Med J 1994;63:193-200. (Pubitemid 24332256)
29. Ochoa JB, Bernard AD, O'Brien WE, Griffen MM, Maley ME, Rockich AK, et al. Arginase I expression and activity in human mononuclear cells after injury. Ann Surg 2001;233:393-9. (Pubitemid 32187819)
30. Tsuei BJ, Bernard AC, Shane MD, Shirley LA, Maley ME, Boulanger BR, et al. Surgery induces human mononuclear cell arginase I expression. J Trauma 2001;51:497-502. (Pubitemid 33009634)